CARTITUDE-10
Phase 2 Clinical Trial Further Evaluating the Safety and Efficacy of Ciltacabtagene-Autoleucel in Participants with Newly Diagnosed Multiple Myeloma in Whom an Autologous Bone Marrow Transplantation is Not Planned
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 2
- Enrollment
- 40 patients (estimated)
- Sponsors
- Johnson & Johnson
- Tags
- CAR T Cell, B-Cell Maturation Antigen (BCMA)
- Trial Type
- Treatment
- Last Update
- SparkCures ID
- 2175
- NCT Identifier
- NCT07149857
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.